Cargando…
Epidemiology of sepsis in a Japanese administrative database
Sepsis is the leading cause of death worldwide. Considering regional variations in the characteristics of patients with sepsis, a better understanding of the epidemiology in Japan will lead to further development of strategies for the prevention and treatment of sepsis. To investigate the epidemiolo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570497/ https://www.ncbi.nlm.nih.gov/pubmed/37841963 http://dx.doi.org/10.1002/ams2.890 |
_version_ | 1785119781504942080 |
---|---|
author | Imaeda, Taro Oami, Takehiko Takahashi, Nozomi Saito, Daiki Higashi, Akiko Nakada, Taka‐aki |
author_facet | Imaeda, Taro Oami, Takehiko Takahashi, Nozomi Saito, Daiki Higashi, Akiko Nakada, Taka‐aki |
author_sort | Imaeda, Taro |
collection | PubMed |
description | Sepsis is the leading cause of death worldwide. Considering regional variations in the characteristics of patients with sepsis, a better understanding of the epidemiology in Japan will lead to further development of strategies for the prevention and treatment of sepsis. To investigate the epidemiology of sepsis, we conducted a systematic literature review of PubMed between 2003 and January 2023. Among the 78 studies using a Japanese administrative database, we included 20 that defined patients with sepsis as those with an infection and organ dysfunction. The mortality rate in patients with sepsis has decreased since 2010, reaching 18% in 2017. However, the proportion of inpatients with sepsis is increasing. A study comparing short‐course (≤7 days) and long‐course (≥8 days) antibiotic administration showed lower 28‐day mortality in the short‐course group. Six studies on the treatment of patients with septic shock reported that low‐dose corticosteroids or polymyxin B hemoperfusion reduced mortality, whereas intravenous immunoglobulins had no such effect. Four studies investigating the effects of treatment in patients with sepsis‐associated disseminated intravascular coagulation demonstrated that antithrombin may reduce mortality, whereas recombinant human soluble thrombomodulin does not. A descriptive study of medical costs for patients with sepsis showed that the effective cost per survivor decreased over an 8‐year period from 2010 to 2017. Sepsis has a significant impact on public health, and is attracting attention as an ongoing issue. Further research to determine more appropriate prevention methods and treatment for sepsis should be a matter of priority. |
format | Online Article Text |
id | pubmed-10570497 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105704972023-10-14 Epidemiology of sepsis in a Japanese administrative database Imaeda, Taro Oami, Takehiko Takahashi, Nozomi Saito, Daiki Higashi, Akiko Nakada, Taka‐aki Acute Med Surg Review Articles Sepsis is the leading cause of death worldwide. Considering regional variations in the characteristics of patients with sepsis, a better understanding of the epidemiology in Japan will lead to further development of strategies for the prevention and treatment of sepsis. To investigate the epidemiology of sepsis, we conducted a systematic literature review of PubMed between 2003 and January 2023. Among the 78 studies using a Japanese administrative database, we included 20 that defined patients with sepsis as those with an infection and organ dysfunction. The mortality rate in patients with sepsis has decreased since 2010, reaching 18% in 2017. However, the proportion of inpatients with sepsis is increasing. A study comparing short‐course (≤7 days) and long‐course (≥8 days) antibiotic administration showed lower 28‐day mortality in the short‐course group. Six studies on the treatment of patients with septic shock reported that low‐dose corticosteroids or polymyxin B hemoperfusion reduced mortality, whereas intravenous immunoglobulins had no such effect. Four studies investigating the effects of treatment in patients with sepsis‐associated disseminated intravascular coagulation demonstrated that antithrombin may reduce mortality, whereas recombinant human soluble thrombomodulin does not. A descriptive study of medical costs for patients with sepsis showed that the effective cost per survivor decreased over an 8‐year period from 2010 to 2017. Sepsis has a significant impact on public health, and is attracting attention as an ongoing issue. Further research to determine more appropriate prevention methods and treatment for sepsis should be a matter of priority. John Wiley and Sons Inc. 2023-10-12 /pmc/articles/PMC10570497/ /pubmed/37841963 http://dx.doi.org/10.1002/ams2.890 Text en © 2023 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Review Articles Imaeda, Taro Oami, Takehiko Takahashi, Nozomi Saito, Daiki Higashi, Akiko Nakada, Taka‐aki Epidemiology of sepsis in a Japanese administrative database |
title | Epidemiology of sepsis in a Japanese administrative database |
title_full | Epidemiology of sepsis in a Japanese administrative database |
title_fullStr | Epidemiology of sepsis in a Japanese administrative database |
title_full_unstemmed | Epidemiology of sepsis in a Japanese administrative database |
title_short | Epidemiology of sepsis in a Japanese administrative database |
title_sort | epidemiology of sepsis in a japanese administrative database |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10570497/ https://www.ncbi.nlm.nih.gov/pubmed/37841963 http://dx.doi.org/10.1002/ams2.890 |
work_keys_str_mv | AT imaedataro epidemiologyofsepsisinajapaneseadministrativedatabase AT oamitakehiko epidemiologyofsepsisinajapaneseadministrativedatabase AT takahashinozomi epidemiologyofsepsisinajapaneseadministrativedatabase AT saitodaiki epidemiologyofsepsisinajapaneseadministrativedatabase AT higashiakiko epidemiologyofsepsisinajapaneseadministrativedatabase AT nakadatakaaki epidemiologyofsepsisinajapaneseadministrativedatabase |